Logic's Mint E-Cigarette Approval Revoked by FDA Center Director Despite Scientists' Advice

Dec.16.2022
Logic's Mint E-Cigarette Approval Revoked by FDA Center Director Despite Scientists' Advice
FDA allowed the director of CTP to disregard scientific advice and revoke approval for Logic's menthol e-cigarette.

Recently, according to the third circuit memorandum of the United States Court of Appeals, lawyers for Logic company alleged that the director of the Center for Tobacco Products (CTP) at the Food and Drug Administration (FDA), Brian King, allowed for the dismissal of recommendations from FDA scientists and revoked the market approval for Logic Technology's menthol electronic cigarette products.


A motion has been filed with Logic Corporation to suspend the marketing injunction (MDO) against its menthol e-cigarette products, and new documents have been provided to the company.


According to lawyers from Troutman Pepper, new documents being reviewed by Vapor Voice reveal an unusual fact: the Center for Tobacco Products' (CTP) Office of Science (OS) revoked its science-based recommendations for the marketing authorization order of Logic's mint-flavored electronic cigarette (ENDS) prior to its pre-market tobacco product application (PMTA) being approved, after pressure from the new CTP director and the Office of Compliance and Enforcement's (OCE) center director.


According to Logic's lawyer, the company claims the right to retain their mint-flavored product in the MDO of the institution because the Office of the Center Director (OCD) overturned the Office of Science's (OS) approval of Logic's "science-based assessment" and preliminary recommendation for their product. However, the memorandum states that mint is classified as a product that will be "disfavored", and Logic is seeking court recognition that the institution's actions, based on an "unpublished, comprehensive policy" and "product-specific decisions" that were not subject to notice or comment rules, were "arbitrary and capricious".


In the October 25 memo, the operating system stated that it evaluated Logic Company's pre-market tobacco product application (PMTA), including its product-specific evidence, and concluded that the authorization of marketing Logic's menthol-flavored ENDS is appropriate for protecting public health (APPH). However, the memo reveals that the operating system only changed course after the director of the new Center for Tobacco Products (CTP) and the Office of Center Director (OCD) reached the conclusion that menthol-flavored ENDS should be considered a "disfavored" product category despite conflicting evidence, as reported by the Office of Science (OS).


The OS memorandum stated, "From a policy perspective, at the time, OS believed that as long as menthol cigarettes were still on the market, menthol-flavored ENDS could directly replace them, providing a less harmful alternative for smokers of menthol cigarettes. Compared to non-menthol smokers, they were less likely to successfully quit smoking.


According to OS, this suggests that there are potential benefits in increasing usage and transition opportunities, and evidence specific to certain products suggests that even ENDS products that are no greater than tobacco-flavored could have a greater potential for smoking cessation or significant reduction in smoking.


Subsequently, OCD raised questions about OS's recommendations, including the adequacy and relevance of scientific literature regarding the differing preferences of adult menthol smokers for menthol, ultimately indicating possible behavioral changes. OCD also highlighted concerns about the significant appeal of menthol to young people. As of July 2022, the decision on Logic PMTA was still pending when CTP transitioned to Brian King as the new center director.


According to a memorandum, OS shared their views with the newly appointed center director and openly discussed various topics including literature, clinical studies related to Logic, usage risks, and potential post-marketing requirements. Following the meeting, a senior scientific consultant specializing in OCD shared their perspective with OS, highlighting the significant risks to young people and the lack of evidence supporting the practical difference between using tobacco flavoring versus menthol flavoring. As a result, the approach to menthol flavoring should be the same as other flavorings, only approving products if evidence shows that the benefits of menthol flavoring outweigh the risks to young people. This led OS to change their direction and their approval of Logic marketing.


The second memo restated the same policy shift and suggested convening a meeting to address concerns raised by operating system personnel about the appropriateness of the decision-making process behind the refusal of Logic peppermint PMTA. The operating system also expressed concern that the new OCD method would eliminate all ENDS products that do not contain tobacco flavors.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

FDA nicotine pouch review delay report knocks tobacco shares lower
FDA nicotine pouch review delay report knocks tobacco shares lower
After Reuters reported before the market open that FDA reviews of nicotine pouch applications could face delays, shares of Philip Morris International, Turning Point Brands and British American Tobacco fell on April 1, underscoring the direct impact of U.S. regulatory signals on major tobacco companies and nicotine pouch expectations.
Apr.02
Special Report | PLONQ Expands in China With New Shenzhen Hub to Accelerate R&D and Partnerships
Special Report | PLONQ Expands in China With New Shenzhen Hub to Accelerate R&D and Partnerships
On March 27, 2026, PLONQ officially opened its upgraded Shenzhen office, reinforcing its long-term commitment to China and marking a new phase of growth. As a leading vape brand in Russia, PLONQ is expanding into new product categories while strengthening R&D, engineering collaboration, and partnerships with Chinese companies. The Shenzhen office will accelerate product development, enhance cooperation with technology and manufacturing partners, and support future growth initiatives.
Apr.01
UKVIA Says VApril 2026 Will Highlight Consumer Impact of Tobacco and Vapes Bill
UKVIA Says VApril 2026 Will Highlight Consumer Impact of Tobacco and Vapes Bill
The UK Vaping Industry Association said it will launch the ninth annual VApril campaign next month. The association described VApril as the world’s largest vape awareness initiative and said it has for almost a decade supported adult smokers looking to quit through vaping by providing evidence-based information, expert insights and practical guidance
Mar.24 by 2FIRSTS.ai
KT&G Overseas Tobacco Revenue Jumps 24.6%, Attracting Global Capital
KT&G Overseas Tobacco Revenue Jumps 24.6%, Attracting Global Capital
South Korean tobacco company KT&G is drawing growing global investor attention after reporting record overseas tobacco sales, with international institutions including Capital Group and BlackRock increasing their stakes.
Business
May.19
Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands reported first-quarter 2026 results on May 7, covering the period ended March 31, 2026. Total consolidated net sales were $124.3 million, up 16.8% year on year. Gross profit was $68.3 million, up 14.6%, while net income fell 19.0% to $11.7 million. Adjusted EBITDA declined 6.5% to $25.9 million.
May.08 by 2FIRSTS.ai
China Boton Group Posts 2025 Revenue of RMB 1.496 Billion, With E-Cigarette Product Revenue Up 4.6%
China Boton Group Posts 2025 Revenue of RMB 1.496 Billion, With E-Cigarette Product Revenue Up 4.6%
China Boton Group reported its results for the year ended December 31, 2025. Revenue was RMB 1.496 billion, down about 9.5% from RMB 1.653 billion in 2024. Gross profit was RMB 377.1 million, with a gross margin of 25.2%, and the group recorded a net loss of RMB 1.000 billion for the year.
Mar.24 by 2FIRSTS.ai